CDR-Life Inc. has announced CDR-609 as its next clinical candidate. Built on the company’s proprietary M-gager platform, ...

T-cell activity is often suppressed by the immunosuppressive nature of the tumor microenvironment, contributing to the ...

Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive ...

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...

Edgewise Therapeutics Inc. CEO Kevin Koch speculated that “perhaps a different environment at the FDA” from four months ago ...

The U.K. National Health Service may or may not deploy transcatheter aortic valve replacement devices as widely as in the U.S., but the National Institute for Health and Care Excellence officially ...

Abvance Therapeutics Inc. secured an undisclosed amount of capital in a seed round led by Zubi Capital to support development ...

Despite the approval of numerous antibody-drug conjugates (ADCs), their therapeutic index remains limited by off-target toxicity resulting from linker instability. To address this challenge, the ...

Visceral leishmaniasis is a fatal disease caused by the Leishmania parasite, affecting organs such as the liver and spleen. Visceral leishmaniasis is considered a neglected tropical disease and is ...

Mira Pharmaceuticals Inc. has reported new in vitro preclinical data supporting the therapeutic potential of SKNY-1, a ...

Forsight Robotics Ltd. secured $125 million in series B financing for its Oryom platform, a robotic system for cataract surgery.

Aprea Therapeutics Inc. has announced new preclinical data on APR-1051, the company’s next-generation oral WEE1 inhibitor, in ...